CJC-1295 with DAC, 2mg

CJC-1295 with DAC is a synthetic modified peptide compound studied for its interactions with growth hormone-releasing hormone (GHRH) receptor pathways in experimental models. The Drug Affinity Complex (DAC) modification — a maleimidopropionyl-lysine moiety at the C-terminus — is studied for its capacity to reversibly bind albumin in experimental systems, producing extended stability compared to the unmodified CJC-1295 variant. The compound is designed with a 30-amino acid sequence structure incorporating four amino acid substitutions that confer enhanced protease resistance relative to native GHRH(1-29). Research applications include GHRH receptor pathway studies, growth hormone secretagogue signalling research, and comparative DAC-modified versus unmodified peptide pharmacology.